Protective effects of telmisartan on heart problems due to medicine (doxorubicin) in patients with breast cancer

Protective effects of telmisartan on cardiac dysfunction in patients with breast cancer on anthracycline (doxorubicin) based adjuvant chemotherapy (PETCAAC Trial) - PETCAAC Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019245

Enrollment

Registered

2019-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: Telmisartan: 40 mg once daily for 6 months Control Intervention1: Placebo: Once daily for six months

Eligibility

Inclusion criteria

Inclusion criteria: Patients with breast cancer Having taken doxorubicin treatment

Exclusion criteria

Exclusion criteria: Baseline LVEF History of heart failure, cardiomyopathy or myocardial infarction. Serum creatinine >=2.5 mg/dl or estimated GFR Known allergy, hypersensitivity or contraindication to any drugs to ACE I or ARBs. Prior chest radiation or chemotherapy. Deranged LFTs like bilirubin >1.5mg/dl and enzymes 2 to 3 times elevated above upper limit of normal. Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Change in global longitudinal strain on myocardial strain imaging using echocardiogram from baseline to completion of the studyTimepoint: 6 months	—

Secondary

Measure	Time frame
Distance covered in 6-minute walk testTimepoint: 6 months	—

Countries

India

Contacts

Public ContactSreenivas Reddy

Govt. Medical College and Hospital

reddycardio2911@gmail.com9417495680

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026